Flying L Partners

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.

TearClear Corp. is an ophthalmic pharmaceutical company based in Boston, Massachusetts, founded in 2015. The company specializes in developing preservative-free therapeutic eye drops for conditions such as glaucoma, dry eye disease, and allergic conjunctivitis. TearClear's innovative platform focuses on improving medication delivery by capturing preservatives before they reach the ocular surface, thereby enhancing patient safety and compliance. The company aims to transform established ophthalmic medications into effective therapies and is actively working on multiple drug candidates to address various eye-related conditions.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, specializing in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions and other diseases with high unmet needs. The company's lead product candidate, TP-03, is currently undergoing Phase IIb/III trials for the treatment of blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. In addition to TP-03, Tarsus is advancing other candidates such as TP-04 for the treatment of rosacea and TP-05 aimed at Lyme disease prophylaxis and malaria reduction. With a focus on addressing significant market opportunities, Tarsus Pharmaceuticals is committed to providing first-in-class therapies where treatment options are currently limited.

CorneaGen is dedicated to advancing cornea care through the development of innovative medical devices, biologics, and therapeutic interventions aimed at eliminating corneal blindness. The company focuses on transforming the practices of corneal surgeons by providing a comprehensive range of services, including high-quality tissue delivery, surgeon education, and advocacy for patient access and reimbursement. By equipping eye surgeons with the latest tools and resources, CorneaGen enhances their ability to restore sight and improve patient outcomes for those affected by corneal conditions.

Oyster Point Pharma, Inc. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, that specializes in the discovery, development, and commercialization of innovative therapies for ocular surface diseases. Founded in 2015, the company is primarily focused on its lead product candidate, OC-01, a nicotinic acetylcholine receptor agonist currently undergoing Phase III clinical trials for the treatment of dry eye disease. This condition, which affects over 30 million Americans, is characterized by a chronic lack of sufficient tears, leading to discomfort and potential vision problems. OC-01 is developed as a nasal spray and aims to restore tear film homeostasis by activating the trigeminal parasympathetic pathway, thereby stimulating natural tear production. Additionally, the company is exploring the use of OC-01 for neurotrophic keratitis, further expanding its therapeutic potential in ocular health.

Surface Pharmaceuticals is a owner and operator of a pharmaceutical company intended to provide ophthalmology products. The company's medicines uses topical formulations with the patented Klarity delivery vehicle, designed to protect and rehabilitate the ocular surface, enabling patients with dry eye disease to recover on time and properly.

CorneaGen is dedicated to advancing cornea care through the development of innovative medical devices, biologics, and therapeutic interventions aimed at eliminating corneal blindness. The company focuses on transforming the practices of corneal surgeons by providing a comprehensive range of services, including high-quality tissue delivery, surgeon education, and advocacy for patient access and reimbursement. By equipping eye surgeons with the latest tools and resources, CorneaGen enhances their ability to restore sight and improve patient outcomes for those affected by corneal conditions.